Business news from Ukraine

Business news from Ukraine

High Temperatures in Bedroom Reduce Sleep Quality by 5–10% — Study

According to Experts Club, elevated air temperatures in the bedroom can significantly impair the quality of nighttime rest, increase wakefulness, and reduce the duration of deep sleep. When the room temperature rises from 25 to 30 degrees Celsius, sleep efficiency in older adults decreases by 5–10%, according to the results of a scientific study published in the journal *Science of The Total Environment*.
Scientists studied the effect of bedroom temperature on the duration, quality, and restlessness of sleep among older adults living in their own homes. The study included 50 participants with an average age of about 79 years. The observations lasted 18 months. The researchers used portable sleep monitors and environmental sensors to measure air temperature and humidity.
The results showed that participants experienced the most restful and effective sleep at air temperatures between 20 and 25 degrees. When the temperature rose to 30 degrees, sleep efficiency decreased by 5–10%.
At the same time, the researchers identified significant individual differences, so the temperature values obtained cannot be considered a universal standard for people of any age.
An additional experimental study, published in the journal *Building and Environment*, also demonstrated the negative impact of high temperatures on the sleep of older adults.
During the experiment, raising the bedroom temperature from 27 to 30 degrees resulted in a 26.3-minute reduction in total sleep duration. Sleep efficiency decreased by 5.5%, the duration of rapid eye movement (REM) sleep decreased by 5.3 minutes, and nighttime wakefulness increased by 27 minutes.
The researchers also found that improved ventilation led to an increase in deep sleep duration by 10.3 minutes and in REM sleep duration by 3.7 minutes.
Experts attribute the effect of temperature to the body’s thermoregulatory mechanisms. Before falling asleep, the body’s core temperature naturally begins to drop. To achieve this, the body redistributes heat to the skin’s surface and releases it into the environment.
If the air temperature is too high, the cooling process becomes more difficult. This can delay the onset of sleep, disrupt the sleep cycle, and increase the number of nighttime awakenings.
According to the scientific review “Thermoregulation in Sleep Disorders,” published on April 12, 2026, in the Journal of Clinical Medicine, disruptions to the natural drop in body temperature are associated with sleep fragmentation and the onset of daytime symptoms, including fatigue and reduced alertness.
Poor-quality sleep can negatively affect concentration, memory, emotional stability, and work performance the following day. At the same time, the severity of these effects depends on the duration and severity of the sleep disturbance, the person’s age, and other factors.
A separate problem during the heating season is the decrease in relative humidity indoors.
Heating cold outdoor air without additional humidification leads to a decrease in its relative humidity. Dry air can cause discomfort in the nose and throat, as well as dryness of the mucous membranes and skin. For some people, this can exacerbate nasal congestion and further interfere with restful sleep.
The U.S. Environmental Protection Agency (EPA) recommends monitoring indoor humidity and ensuring it does not exceed 50% when using household humidifiers. Excessive humidity can promote the growth of mold and other biological contaminants.
According to the Sleep Foundation’s recommendations, for many adults, a comfortable bedroom temperature falls within the range of 16–20 degrees Celsius. However, choosing the optimal setting depends on individual characteristics, age, sleepwear, and the blankets used.
In particular, studies of older adults suggest that in some cases, higher temperatures—around 20–25 degrees—may be most beneficial.
To improve sleep conditions, experts recommend avoiding overheating the bedroom, regularly ventilating the room, using seasonally appropriate bedding, and controlling humidity levels.

https://www.experts.news/posts/vysoka-temperatura-u-spalni-znyzhuye-yakist-snu-na-510-doslidzhennya

 

, , , ,

Sales at pharmacies in Ukraine over the first 9 months rose by 16.7% in monetary terms but fell by 5% in volume terms

Pharmacy sales in Ukraine for the January–September 2026 period rose by 16.7% in monetary terms compared to the same period in 2025—reaching nearly 186.387 billion UAH, while in volume terms, they fell by 5%, to nearly 802.242 million packages, the company “Business Credit” reported to the Interfax-Ukraine news agency, citing a study it conducted.

According to the report, the weighted average price of the pharmacy basket for the period in question was 232.33 UAH per package, which is 22.91% higher than during the same period a year earlier.
At the same time, pharmacy sales of medicines increased by 23.12% in monetary terms—to more than 152.26 billion UAH—and by 6.34% in volume terms—to nearly 634.961 million packages.

The weighted average retail price of pharmaceuticals for the first nine months of 2026 was 239.79 UAH per package, which is 15.79% higher than in January–September 2025.
At the same time, pharmacy sales of dietary supplements in the first nine months of 2026 increased by 7.5% in monetary terms—to nearly 19.764 billion UAH—while in volume terms they decreased by 17.7%—to 59.913 million packages. The weighted average price in this segment rose by 30.72%—to 329.88 UAH per unit.

Business Credit notes that from January through September 2026, the highest price increases in pharmacy retail were seen in products for parenteral administration of medications (syringes, injection needles, infusion sets/drip sets/transfusion sets, catheters—IF-U), which rose in price by 53.47%.
Overall, according to the company’s data, in the pharmacy retail sector over the first nine months of 2026, sales volumes in monetary terms decreased across all product categories except dietary supplements (+7.5%), therapeutic cosmetics (+21.4%), and mineral water (+4.8%).

At the same time, in volume terms, pharmacy sales increased only in the pharmaceuticals category.

As previously reported, pharmacy sales in Ukraine for the period from January through August 2026 increased by 15.7% in monetary terms compared to the same period in 2025—to more than nearly 162 billion UAH—while in volume terms, they decreased by 5.86%, to nearly 707,313 thousand packages. The weighted average price of items in the pharmacy basket for the period was 229.76 UAH per package, which is 22.88% higher than during the same period a year earlier.

At the same time, pharmacy sales of pharmaceuticals increased by 21.32% in monetary terms—to nearly 132.199 billion UAH—and by 5.13% in volume terms—to nearly 556.962 million packages. The weighted average retail price of medicines for the first eight months of 2026 was 237.36 UAH per package, which is 15% higher than in January–August 2025.

For the full year 2025, pharmacy sales in monetary terms increased by 14.23% compared to 2024—to more than 220.287 billion UAH—while in volume terms, they decreased by 2.25%, to nearly 1.135 million packages. The weighted average price of items in the pharmacy basket was 194.68 UAH per package, which is 16.86% higher than a year earlier. Pharmacy sales of medicines in 2025 increased by 12.79% in monetary terms—to nearly 170.318 billion UAH—while in volume terms, they decreased by 0.2% compared to 2024, to 808.546 million packages. The weighted average retail price of pharmaceuticals at the end of 2025 was 210.65 UAH per package, which is 13% higher than at the end of 2024.

, , , ,

Scientists Have Found Link Between Brisk Walking and Increased Life Expectancy — Study

According to Experts.news, an international team of scientists has found that a person’s walking speed and step frequency in daily life are linked to the risk of premature death. An analysis of data from more than 4,000 participants showed that people who walked faster had, on average, a lower risk of death during the subsequent years of follow-up.

The study’s findings were published on October 23, 2026, in the scientific journal JAMA Network Open. The study involved researchers from the Norwegian University of Science and Technology, the University of Paris-Cité, the University of Leicester, and other academic institutions.

The study was based on the British long-term Whitehall II project. The researchers analyzed data from 4,067 people, whose average age at the start of the study was 69.3 years. Men accounted for 74.4% of the participants, and women for 25.6%.

In 2012–2013, participants underwent walking speed tests over a distance of 2.44 meters and wore wrist-mounted accelerometers to record their daily physical activity.

On average, the devices recorded data for nearly eight days. The researchers assessed not only the number of steps taken but also walking frequency, expressed in steps per minute.

The participants’ average speed during clinical testing was 1.2 meters per second, and the median walking frequency in daily life was 75.3 steps per minute.

Further health follow-up continued for an average of 11.8 years. During this period, 739 people—or 18.2% of the study participants—died.

An increase in walking speed of 0.1 meters per second is associated with a 10% reduction in the risk of death

After adjusting for age, sex, education, smoking, alcohol consumption, body mass index, chronic diseases, and other factors, the researchers found a consistent association between walking speed and mortality.

Specifically, an increase in walking speed during the clinical test by 0.1 meters per second corresponded to a reduction in the relative risk of death during the follow-up period of approximately 10%.

When the median walking rate in daily life increased by 10 steps per minute, the corresponding risk was 17% lower.

An even stronger association was observed when analyzing the 95th percentile of step rate, which characterizes relatively fast periods of walking.

An increase in this measure by 10 steps per minute was associated with a reduction in the relative risk of death of approximately 19%.

The authors note that the identified associations persisted even after further adjusting for the total number of steps per day.

Thus, to assess health status, it is potentially important to consider not only the volume of physical activity but also walking pace.

However, the percentage figures identified reflect statistical associations rather than a proven effect of increased walking speed on life expectancy.

“Smart” watches could serve as an additional tool for health assessment

One of the study’s main objectives was to compare two methods of assessing walking: short-term clinical testing and the measurement of daily activity using portable electronic devices.

The researchers found that both methods demonstrated comparable ability to distinguish between participants with higher and lower mortality risk.

However, when all known risk factors were included in the statistical models, only clinical measurement of walking speed provided a statistically significant additional improvement in mortality prediction.

The researchers believe that data from smartwatches and other wearable devices can complement traditional medical examinations, as they allow for the monitoring of a person’s physical activity under normal conditions over the course of several days.

Unlike a brief test at a medical facility, accelerometers record patterns of everyday behavior and can be used to study changes in physical activity.

At the same time, the authors emphasize that clinical walking speed and step frequency, as measured by wearable devices, are not interchangeable indicators.

The authors note a number of limitations to the study. In particular, participants were, on average, healthier than the baseline cohort, and men accounted for nearly three-quarters of the sample.

Furthermore, the study was observational in nature and did not include an experiment in which participants were specifically trained to walk faster.

Therefore, the results do not provide grounds for asserting that a simple increase in walking speed directly reduces mortality by 10–19%.

A higher walking speed may indicate better overall health, physical fitness, and functional capacity.

At the same time, the researchers believe that assessing walking speed could become a useful additional tool for studying the health of older adults.

Further research is needed to implement this approach, particularly involving more diverse populations and independent validation of prognostic models.

The study, titled Clinical Walking Speed, Free-Living Walking Cadence, and All-Cause Mortality, was published in JAMA Network Open on October 23, 2026. The lead author was Rayane Haddadj of the Norwegian University of Science and Technology. The study was supported by European research programs, specifically Horizon Europe.

Source: JAMA Network Open, original study from October 23, 2026. DOI: 10.1001/jamanetworkopen.2026.40122.

, , , ,

Ukrainian molecular genetics laboratory “GenCode Diagnostics” invested $500,000 in its development in 2026

The Ukrainian full-cycle molecular genetics laboratory “GenCode Diagnostics” invested approximately $1.3 million in the company’s development between 2023 and 2026, including $600,000 this year, according to Oleksandr Vlasyshen, co-founder and CEO of the Ukrainian laboratory “GenCode Diagnostics.”

“We are growing with the ‘gold standard’ in mind and are currently purchasing the latest equipment. Specifically, in 2026, over $500,000 was invested in the acquisition of two state-of-the-art next-generation sequencing systems—the Illumina NextSeq 1000 and the MGI DNBSEQ-G400. Together, they enable the processing of approximately 480 samples for non-invasive prenatal testing in a single full run cycle,” Vlasyshen told the Interfax-Ukraine news agency.

At the same time, the company is investing in the development of laboratory infrastructure and the training of specialists. Over the company’s three years of operation, approximately $100,000 has been allocated to team training, method validation, and certification.
In light of current challenges, the company has also invested in power equipment.

“Some tests last up to 28 hours. That’s why our system (inverters + batteries + generator) has a 64-hour power reserve,” he said.

In 2027, GenCode Diagnostics plans to complete accreditation under the international ISO 15189 standard, automate DNA extraction and sample preparation processes, and increase NIPT capacity to 1,000 tests per month. In the coming years, the company plans to further expand its equipment fleet, develop oncogenetics and exome sequencing, and create its own bioinformatics platform. The company plans to enter Eastern European markets by 2029.

“The long-term goal by 2030 is to establish a leading national reference center for genetic diagnostics capable of providing a full cycle of modern genetic testing in Ukraine,” Vlasyshen said.

“GeneCode Diagnostics” is a Ukrainian full-cycle molecular genetics laboratory founded in 2023. All tests are performed in accordance with international standards for genetic testing, while complying with Ukrainian and international data protection regulations. The CEO and co-founder is Oleksandr Vlasyshen. According to YouControl, the company’s authorized capital is 8 million UAH, and its net profit in the first half of 2026 was 738,500 UAH.

, , , ,

Ukrainian MedTech startup CheckEye receives $175,000 at international competition in the US

Ukrainian medical startup CheckEye, which is developing an artificial intelligence system for the early detection of chronic diseases using retinal images, has received a $175,000 award at the international Healthy Longevity Global Competition organized by the US National Academy of Medicine (NAM). The company took second place in the final stage of the competition, NAM reported.

The award ceremony took place in Washington during the international NAM Global Innovator Summit. The Ukrainian team was represented by CheckEye co-founder Viktoriia Chuchyna, who was identified by the organizers as the leader of the competition project.

The Ukrainian company’s development, called AI-Powered Retinal Screening for Early Detection of Chronic Diseases, involves using artificial intelligence to analyze retinal images and identify signs of chronic diseases.

The technology allows examinations to be conducted without complex invasive procedures. According to the company, capturing an image of the fundus takes about three minutes, after which the image is analyzed by a cloud-based platform using artificial intelligence algorithms.

The examination can be conducted in primary healthcare facilities, pharmacies and specialized screening centers without the direct involvement of an ophthalmologist at the image acquisition stage.

Currently, the platform is primarily focused on detecting diabetic retinopathy and signs of vascular diseases, including arterial hypertension. In the future, the developers intend to expand the technology’s capabilities to assess the risks of more than 50 diseases.

According to the project description submitted to the competition organizers, CheckEye has already screened more than 15,000 people in five countries: Ukraine, Germany, Austria, Romania and the United Kingdom.

The company reports that its algorithms achieve a sensitivity of 93–95% in detecting diabetic retinopathy and a specificity of approximately 90%. These figures are presented in the competition documentation and represent the development results claimed by the team.

As part of a pilot program of Ukraine’s Ministry of Health, implemented from October 2024 to March 2025 in Odesa and Chernihiv regions, more than 870 patients with diabetes underwent screening. According to the project, approximately one-quarter of the participants were referred for treatment.

The company plans to use the $175,000 received from the competition to scale up the technology and further develop methods for the early diagnosis of chronic diseases.

“It is a great honor for us to represent and promote Ukrainian innovations around the world. This recognition at the global level confirms that our technology has the potential to change the approach to treating chronic diseases — from dealing with their consequences to early prevention,” CheckEye founder and CEO Kyrylo Honcharuk said in a company statement.

According to NAM, 147 applications from participants who had previously received support from the program were considered in the final stage of the Healthy Longevity Global Competition. Fourteen projects became winners in various categories, sharing $2 million in awards.

Two projects received the top prizes of $700,000 each, while two others, including Ukraine’s CheckEye, took second place and received $175,000 each. The third prize amounted to $125,000, and nine other projects received honorable mention awards.

In total, over the seven years of the international program, launched by NAM in 2019, its organizers and partners have supported more than 725 projects with over $38 million in funding. The program covered more than 50 countries and territories.

For CheckEye, the award marked another stage of international recognition. The Ukrainian startup previously received support from EIT Health, the European Bank for Reconstruction and Development and Google for Startups, and also won the EIT Health InnoStars Awards 2024.

According to NAM, the total amount of support attracted by CheckEye before receiving the latest award exceeded $750,000.

CheckEye is a Ukrainian HealthTech company specializing in the development of medical screening technologies using artificial intelligence. Its platform is designed for the early detection of diseases based on retinal image analysis and for expanding access to preventive examinations. The company’s founder and CEO is Kyrylo Honcharuk.

, , , , ,

ADONIS Medical Center Opens Sleep Lab to Diagnose Sleep Disorders

ADONIS Medical Center launched its sleep lab on October 26, 2026; the facility will specialize in the diagnosis and treatment of sleep disorders, according to the medical network’s press office.

The lab offers patients two types of testing: overnight polysomnography in a specially equipped clinic room and at-home sleep studies using portable diagnostic equipment.

Polysomnography allows for a comprehensive assessment of physiological processes during sleep, including sleep structure, breathing, heart rate, and blood oxygen saturation levels. During overnight testing at the clinic, medical staff monitor the equipment’s operation and the quality of the recorded data.

According to the medical center, the room for overnight studies is located directly within the clinic’s shelter, which ensures that the examination is not interrupted during air raid alerts.

For at-home testing, the patient receives a portable device and instructions on how to use it. After the procedure is complete, the equipment is returned to the clinic for analysis of the collected data.

A medical report is prepared within 2–3 business days. Afterward, the patient can consult with a neurologist, who will explain the test results and provide recommendations for further treatment.

If necessary, specialists from various fields—including cardiologists, neurologists, endocrinologists, and psychotherapists—will be involved in the diagnosis and treatment.

ADONIS notes that this specialized examination may be relevant for people who experience regular loud snoring, sleep apnea, frequent nighttime awakenings, morning headaches, constant fatigue upon waking, or excessive daytime sleepiness. Such symptoms may indicate, among other things, obstructive sleep apnea.

The opening of the laboratory comes amid a decline in sleep quality among some Ukrainians due to the full-scale war, constant stress, and nighttime air raid alerts.

The ADONIS Sleep Laboratory is located at: Kyiv Oblast, Sofiivska Borshchahivka village, 90 Akademika Shalimova St.
ADONIS is a Ukrainian network of multidisciplinary medical centers for adults and children, founded in Kyiv in 1997. The network provides medical services across numerous specialties, including diagnostics, outpatient care, and surgical treatment. According to the company, its network includes medical centers in Kyiv and the Kyiv region.

, , , ,